Results 61 to 70 of about 176,622 (333)

Positive Feedback Loop of Histone Lactylation‐Driven HNRNPC Promotes Autophagy to Confer Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance

Advanced Science, EarlyView.
Histone 3 lysine18 lactylation (H3K18la) drives heterogeneous nuclear ribonucleoprotein C (HNRNPC) overexpression, activating autophagy to mediate gemcitabine resistance by stabilizing TNF receptor‐associated factor 6 (TRAF6) mRNA. Concurrently, HNRNPC stabilizes aldehyde dehydrogenase 1 family member A3 (ALDH1A3) mRNA, which enhances glycolysis and ...
Xi‐Tai Huang, Jiao Chen, En‐Liang Zhu, Ming‐Jian Ma, Yang‐Yin‐Hui Yu, Ying‐Qin Zhu, Jing‐Yuan Ye, Jin‐Zhao Xie, Zi‐Yi Zhao, Xiao‐Yu Yin   +9 more
wiley   +1 more source

A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma

Clinical Medicine Insights: Oncology, 2008
Background Bevacizumab and irinotecan may represent one of the most active treatments in progressive malignant glioma. Limited published experience with bevacizumab in patients with CNS tumors raises concerns regarding toxicity, particularly in regards ...
Tina Mayer, Jill Lacy, Joachim Baehring M.D.   +2 more
doaj   +1 more source

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer

Frontiers in Oncology, 2022
BackgroundBevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer.
Seijong Kim, Jung Kyong Shin, Yoonah Park, Jung Wook Huh, Hee Cheol Kim, Seong Hyeon Yun, Woo Yong Lee, Yong Beom Cho, Yong Beom Cho, Yong Beom Cho   +9 more
doaj   +1 more source

Weekly versus three weeks chemotherapy for advanced ovarian cancer. A meta-analysis [PDF]

, 2016
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear.
De Felice, Francesca, Marchetti, Claudia, Monti, Marco, Musella, Angela, Musio, Daniela, Muzii, Ludovico, Palaia, Innocenza, Panici, Pierluigi Benedetti, Tombolini, Vincenzo   +8 more
core   +1 more source

Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring

Advanced Science, EarlyView.
Scars exhibit vascular abnormal alterations, including upregulated NRP1 expression in endothelial cells, increased vascular density and branching, compromised vessel wall integrity, and incomplete pericyte coverage. Therapeutic targeting of NRP1 through hydrogel spray delivery offers a promising approach to normalize aberrant vasculature and prevent ...
Yu Wang, Xin Zhou, Min Liu, Meimei Huang, Peirong Chen, Xinying Li, Fangchao Xue, Wenyan Zhao, Di Liu, Lang Li, Yuangang Lu, Wen Zeng   +11 more
wiley   +1 more source

CENTRAL MACULAR THICKNESS AFTER COMBINED THERAPY OF BEVACIZUMAB INTRAVITREAL INJECTION AND TOPICAL DICLOFENAC COMPARED WITH BEVACIZUMAB INTRAVITREAL INJECTION ALONE IN DIABETIC MACULAR EDEMA

IJRETINA (International Journal of Retina), 2021
Introduction: To evaluate whether the combination of diclofenac eye drops and bevacizumab intravitreal injection would provide additional benefits over bevacizumab alone in the treatment of naïve diabetic macular edema (DME).
Melvina Nidya Sandra, Yumni Shabrina, Tri Wahyu Widayanti, Retno Ekantini, Agus Supartoto, Muhammad Bayu Sasongko, Supanji Haryanto   +6 more
doaj   +1 more source

Who Is In Charge, and Who Should Be? The Disciplinary Role of the Commander in Military Justice Systems [PDF]

, 2006
BackgroundStandard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma ...
Abrey, Lauren, Brandes, Alba A., Carpentier, Antoine F., Cernea, Dana, Chinot, Olivier L., Cloughesy, Timothy, Henriksson, Roger, Hilton, Magalie, Hoang-Xuan, Khe, Kavan, Petr, Mason, Warren, Nishikawa, Ryo, Saran, Frank, Wick, Wolfgang   +13 more
core   +3 more sources

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies

Advanced Science, EarlyView.
ARID1A, a SWI/SNF complex component, is frequently mutated in colorectal cancer (CRC). CRC with ARID1A/TP53 concurrent mutations shows marked sensitivity to WEE1 inhibition. ARID1A loss induces R‐loop‐mediated replication stress, impairs ATF3 transcription, and amplifies WEE1i‐induced DNA damage, suggesting a promising therapeutic vulnerability ...
Chi Zhang, Yanjing Zhu, Luoyan Ai, Jingyuan Wang, Shan Yu, Yichen Wang, Xiaojing Xu, Mengling Liu, Yiyi Yu, Mengxuan Zhu, Yutong Liu, Zhenghang Xu, Haojie Zhou, Huishan Li, Qihong Huang, Qing Liu, Ke Peng, Tianshu Liu   +17 more
wiley   +1 more source

Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild‐type KRAS exon 2 metastatic colorectal cancer

Cancer Medicine, 2019
Purpose Combination of biological therapy and chemotherapy improves the survival of patients with metastatic colorectal cancer (mCRC). However, the optimal biological therapy sequence remains unclear.
Hung‐Chih Hsu, Yu‐Chun Liu, Chuang‐Wei Wang, Wen-Chi Chou, Yu-Jen Hsu, Jy-Ming Chiang, Yung-Chang Lin, Tsai-Sheng Yang   +7 more
doaj   +1 more source

Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated With Atezolizumab Plus Bevacizumab

Liver Cancer, 2022
Introduction: In the Phase 3 IMbrave150 trial (NCT03434379), atezolizumab + bevacizumab demonstrated a clinically meaningful survival benefit over sorafenib in patients with unresectable hepatocellular carcinoma (HCC), including those with hepatitis B ...
Chiun Hsu, Michel Ducreux, Andrew X. Zhu, Shukui Qin, Masafumi Ikeda, Tae-You Kim, Peter R. Galle, Richard S. Finn, Ethan Chen, Ning Ma, Youyou Hu, Lindong Li, Ann-Lii Cheng   +12 more
doaj   +1 more source